MetaVia Inc.
Business
MetaVia Inc. is a clinical-stage biotechnology company developing novel pharmaceuticals to treat cardiometabolic diseases. The company's primary focus is vanoglipel (DA-1241), a GPR119 agonist in Phase 2a trials for metabolic dysfunction-associated steatohepatitis and Type 2 Diabetes, and DA-1726, a GLP-1/glucagon dual agonist in Phase 1 trials for obesity. MetaVia operates in the United States and has legacy programs in viral, neurodegenerative and cardiometabolic indications available for out-licensing.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 7 | 22 | — | — | — | |
| General and administrative | 7 | 7 | 7 | 9 | 9 | |
| Total operating expenses | 14 | 29 | — | — | — | |
| Loss from operations | −14 | −29 | −16 | −20 | −15 | |
| Gain from change in fair value of warrant liabilities | 225,000 | 297,000 | 3 | 8 | — | |
| Interest income, net | 510,000 | 920,000 | 461,000 | — | 14,000 | |
| Total other income | 735,000 | 1 | 3 | 6 | 14,000 | |
| Loss before income taxes | −13 | −28 | −12 | −14 | −15 | |
| Provision for income taxes | 0 | 0 | 0 | 0 | 0 | |
| Net loss | −13 | −28 | −12 | −14 | −15 | |
| Loss per share of common stock, basic (in dollars per share) | −7.35 | −39.13 | −2.46 | −43.42 | −19.81 | |
| Loss per share of common stock, diluted (in dollars per share) | −7.35 | −39.13 | −2.46 | −43.42 | −19.81 | |
| Weighted average shares of common stock, basic (in shares) | 2 | 705,193 | 5 | 321,703 | 771,422 | |
| Weighted average shares of common stock, diluted (in shares) | 2 | 705,193 | 5 | 321,703 | 771,422 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 10 | 16 | 22 | 33 | 16 | |
| Prepaid expenses and other current assets | 597,000 | 55,000 | 77,000 | 168,000 | — | |
| Total current assets | 11 | 16 | 23 | 34 | 17 | |
| Property and equipment, net | 17,000 | 34,000 | 46,000 | 2,000 | 110,000 | |
| Right-of-use asset | 210,000 | 133,000 | 202,000 | — | 105,000 | |
| Other assets | 21,000 | 21,000 | 21,000 | — | — | |
| Total assets | 11 | 16 | 23 | 34 | 17 | |
| Accounts payable | 1 | 4 | 821,000 | 708,000 | 830,000 | |
| Clinical trial accrued liabilities | 79,000 | 2 | 3 | — | — | |
| Accrued expenses and other current liabilities | 993,000 | 785,000 | 592,000 | — | — | |
| Warrant liabilities | 136,000 | 361,000 | 658,000 | 11 | — | |
| Related party payable | 3 | 1 | 789,000 | — | — | |
| Lease liability, short-term | 68,000 | 78,000 | 67,000 | — | 26,000 | |
| Total current liabilities | 6 | 8 | 6 | 12 | 2 | |
| Lease liability, long-term | 142,000 | 58,000 | 136,000 | — | 45,000 | |
| Total liabilities | 6 | 8 | 6 | 12 | 2 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Preferred stock, $0.001 par value per share; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2025 and 2024; 2,308,294 and 785,194 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2,000 | 1,000 | 5,000 | 25,000 | 1,000 | |
| Additional paid-in capital | 154 | 144 | 125 | 118 | 96 | |
| Accumulated deficit | −149 | −136 | −108 | −96 | −82 | |
| Total stockholders' equity | 5 | 8 | 17 | 22 | 15 | |
| Total liabilities and stockholders' equity | 11 | 16 | 23 | 34 | 17 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 411,000 | 538,000 | 222,000 | 854,000 | 662,000 | |
| Non-cash lease (credit) charge | −3,000 | 4,000 | — | — | — | |
| Depreciation | 19,000 | 20,000 | 6,000 | 20,000 | 48,000 | |
| Prepaid expenses and other assets | −542,000 | 20,000 | 70,000 | 64,000 | — | |
| Accounts payable | −3 | 3 | 113,000 | −202,000 | −1 | |
| Accrued and other liabilities | 431,000 | −461,000 | 4 | −1 | 182,000 | |
| Net cash used in operating activities | −16 | −25 | −11 | −12 | −15 | |
| Purchases of property and equipment | −2,000 | −8,000 | −50,000 | — | −3,000 | |
| Net cash used in investing activities | −2,000 | −8,000 | −50,000 | 8,000 | −586,000 | |
| Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering | 10 | 20 | — | — | — | |
| Proceeds from exercise of warrants | 6,000 | 1,000 | — | — | — | |
| Payment of employee withholding taxes related to shares withheld from issuance for vested restricted stock units | −12,000 | −48,000 | — | — | — | |
| Net cash provided by financing activities | 10 | 18 | −80,000 | 29 | 22 | |
| Net decrease in cash and cash equivalents | −6 | −6 | −11 | 17 | 6 | |
| Fair value of warrants issued to placement agent | — | 309,000 | — | — | — | |
| Right-of-use assets obtained in exchange for operating lease liabilities | 152,000 | — | 223,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is MetaVia Inc.'s CIK number?
MetaVia Inc.'s SEC CIK number is 0001638287 (1638287). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find MetaVia Inc.'s SEC filings?
All of MetaVia Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did MetaVia Inc. last report earnings?
MetaVia Inc. (MTVA) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-061148). This is MetaVia Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is MetaVia Inc.'s most recent earnings 8-K?
MetaVia Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001104659-26-061148. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View MetaVia Inc.'s latest earnings 8-K →
Look up any company's CIK number →